RESI @ JPM Will Soon Be SOLD OUT Redefining Early Stage Investments Conference at 75% Capacity with Only a Month to Go—Carpe Diem

8 Dec

By Dennis Ford, Founder & CEO, LSN

A year ago, we were delighted by the demand for RESI San Francisco, and to our surprise we had to close registrations two weeks early as we’d reached capacity. We have increased space over last year – however, RESI @ JPM at the Marines’ Memorial Club is fast approaching sellout at 75% of capacity, and is expecting to host over 2000 scheduled and ad hoc meetings in one high energy day. This is a record-setting pace for Life Science Nation and the RESI Conference. We expect to close registration well before January 10th, perhaps even before New Year’s Day!

The growth of RESI into a must-go-to event during JPMorgan week, is owed to our near-equal ratio of investors to fundraising executives paired with our unique partnering platform rich with investor data – an amazing feat that is only possible due to the strength of LSN’s investor network.  Considering how hard it is to get in front of investors that are a fit for your stage of development and product, the opportunity to meet with this many investors who are mandated to find early stage firms in your space is one that serious entrepreneurs cannot afford to miss. The success of the RESI conference series is proof of that.

Carpe diem, register today, and do not miss this great opportunity to find the right investor at the right time for your technology!

resi-san-francisco-2017

Matching Fundraising Executives with Investors – RESI Partnering Tutorial

8 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

With RESI partnering having launched this week we wanted to provide a quick video tutorial on how to use the platform most effectively. The video below shows a step by step demonstration of the platform and how it can be used to parse through and identify the hundreds of companies and investors that will be in attendance on January 10th. By using this platform, you can identity relevant groups and book up to 16 meetings throughout the day.

With full investor and company profiles capturing data including the stage and sector that of a company’s technology as well as where investors are looking to allocate, this system is extremely powerful in helping to identify matches on the basis of a mutual fit. The sooner you log in and start requesting meetings the better. If you have yet to register and receive your RESI Partnering access info, time is of the essence as schedules will fill up quickly. I hope to see you in San Fran – good luck in partnering!

RESI San Francisco Panel Announcement: Medical Device Investors

8 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

The various panels that run throughout the day at every RESI conference serves to educate entrepreneurs on how various investors (VCs, corporates, angels, family offices, etc.) are looking at innovation in their specific sector and tactical guidance for how to approach and interact with them, including the nuances of commercializing these technologies and current happenings in their respective market. Medtech, especially in recent years, has taken a backseat to biopharma with lower valuations and fewer exit partners, however many early-stage investors and entrepreneurs alike, still believe there is value to be unlocked.

During RESI@JPM, a group of seasoned medical device investors will explore the state of the early-stage medtech space, discuss personal successes and failures in funding novel medical technologies and share with the entrepreneurs in the audience do’s and don’ts of fundraising in this challenging sector.

Medical Device investor panelists will include the following:

By registering for RESI San Francisco, you’ll be able to listen to the Medical Device investors panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

resi-san-francisco-2017

Hot Investor Mandate 1: Singapore Fund Invests in Clinical Stage Biopharma, Devices and Digital Health

8 Dec

A venture capital firm based in Singapore makes early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities.

The firm seeks to invest in biopharmaceuticals, medical devices and digital health. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. In digital health, the firm looks for companies targeting wellness, chronic diseases and distributed care.

The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Major Medtech Firm Looking Early for Information-Enabled Devices, Delivery Devices and Point of Care Diagnostics

8 Dec

A leading medical technology company partners with companies from their formation through to commercialization, including expansion of operations and channel access.   The firm considers a variety of engagement models including research collaborations, licenses, investments and acquisition when partnering with companies aligned with their core businesses and new areas of strategic interest, seeking opportunities from around the globe.

The firm is currently seeking innovative companies working in sectors of medical technology, diagnostics, and healthcare IT. Within these areas, the firm is most interested in technologies including Information enabled devices, healthcare data analytics, parenteral delivery, patient and healthcare worker safety, microfluidics and point-of-care diagnostics, specimen collection and preservation, next generation sequencing, and developing world / maternal and newborn health. The firm considers opportunities in these areas on a case-by-case basis.

The firm prefers to partner with experienced management teams with a track record of accomplishment including graduates from respected accelerators and incubators, providing in-kind support to advance business plan development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: European Firm Raises New Fund for Biotech and Medical Device Opportunities

8 Dec

A venture capital firm based in Europe focuses solely on the life sciences. The firm recently closed their third fund and is actively looking for new investments, usually in series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount up front, in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America.

The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that address inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Venture Firm Invests in Therapeutic Platforms, Diagnostics, Digital Health and Home Care

8 Dec

A California-based VC firm raised its first fund in 2016. The firm invests in early stage healthcare technologies that are strategically relevant to its LPs, which are major healthcare corporations. The firm is a multi-stage investor, interested in companies from the seed stage through to late-stage venture rounds. Investments therefore vary by stage, but the firm’s Series A investments may typically be of about $1-3 million. The firm generally prefers to act as a co-investor, and is focused on US-based opportunities.

The firm is interested in new technologies in digital health, diagnostics, home care technology, and also therapeutics in musculoskeletal disease, respiratory disease and cardiovascular and metabolic diseases. The firm’s primary focus is on the intersection between data and biotech, diagnostics and medical devices, with microfluidics, connected devices, digitization, and automation being areas of high interest. For therapeutics, the firm generally does not invest in single-asset companies; therapeutic platform technologies that have the potential to create multiple ‘shots on goal’ are preferred. The firm prefers to focus on patients for whom there is high unmet need and no currently adequate treatments; rare diseases are of high interest. The firm is a multi-stage investor, and is open to investing in assets as early as the preclinical or pre-prototype stage.

The firm seeks management teams that display knowledge of how to build a business out of a strong technology. The firm focuses on technologies that allow the firm’s LPs to provide a value-add in partnering, manufacturing or distribution; healthcare technologies involving sensors and materials science are high focus areas. The firm evaluates opportunities on a technical, clinical and leadership level; the firm then shares the results of their diligence with the company in order to help the company in their future efforts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com